{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: GI-001\nAge: 58\nCancer Type: Melanoma\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Ondansetron 8mg PRN, Lisinopril 10mg daily\n\nLABORATORY VALUES:\nWBC: 11.2 x10^9/L (H), CRP: 2.8 mg/dL (H), Albumin: 3.2 g/dL (L), Hemoglobin: 12.5 g/dL\n\nSYMPTOMS:\nDiarrhea - 5-6 loose stools daily for 4 days, Abdominal cramping - mild, No blood in stool, No fever\n\nCLINICAL NOTES:\nPatient on cycle 4 of pembrolizumab for stage IIIC melanoma. Reports onset of loose stools 4 days ago, now having 5-6 episodes daily. Mild periumbilical cramping. No mucus or blood. Appetite slightly decreased. No recent antibiotic use. No sick contacts.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 2 - Moderate\",\n  \"urgency\": \"soon\",\n  \"affected_systems\": [\n    \"Gastrointestinal\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Possible\",\n    \"reasoning\": \"Patient on PD-1 inhibitor (pembrolizumab) with new onset diarrhea 5-6 stools/day consistent with CTCAE Grade 2 colitis. Timing during cycle 4 is typical for immune-related colitis. No infectious etiology identified.\",\n    \"temporal_relationship\": \"Onset during active immunotherapy treatment\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"Classic Grade 2 diarrhea pattern\",\n      \"No alternative cause identified\"\n    ],\n    \"against_factors\": [\n      \"No blood in stool\",\n      \"No fever\"\n    ]\n  },\n  \"severity_reasoning\": \"CTCAE Grade 2 Diarrhea: 4-6 stools/day over baseline. Patient reports 5-6 loose stools daily which meets Grade 2 criteria.\",\n  \"urgency_reasoning\": \"Grade 2 GI toxicity requires oncology review within 1-3 days to assess need for immunotherapy hold and corticosteroid initiation.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Hold pembrolizumab pending evaluation\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 2 colitis typically requires treatment hold\"\n    },\n    {\n      \"action\": \"Start oral prednisone 1mg/kg daily\",\n      \"priority\": 1,\n      \"rationale\": \"Standard first-line treatment for Grade 2 colitis\"\n    },\n    {\n      \"action\": \"Obtain stool studies to rule out infectious etiology\",\n      \"priority\": 2,\n      \"rationale\": \"Must exclude C. diff and other infections\"\n    }\n  ],\n  \"key_evidence\": [\n    \"5-6 loose stools daily\",\n    \"On pembrolizumab\",\n    \"Elevated CRP\",\n    \"Low albumin\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: GI-002\nAge: 65\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nNivolumab 480mg IV q4weeks, Prednisone 10mg daily (started 2 days ago), Loperamide 2mg PRN\n\nLABORATORY VALUES:\nWBC: 14.5 x10^9/L (H), CRP: 8.5 mg/dL (H), Albumin: 2.8 g/dL (L), Potassium: 3.2 mEq/L (L), Creatinine: 1.4 mg/dL (H)\n\nSYMPTOMS:\nDiarrhea - 8-10 watery stools daily, Blood in stool - present, Severe abdominal pain, Fever - 38.2\u00b0C, Dehydration signs\n\nCLINICAL NOTES:\nPatient on nivolumab for metastatic NSCLC. Severe watery diarrhea started 1 week ago, now with visible blood. Diffuse abdominal tenderness on exam. Signs of dehydration. Started low-dose prednisone 2 days ago without improvement.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 3 - Severe\",\n  \"urgency\": \"urgent\",\n  \"affected_systems\": [\n    \"Gastrointestinal\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on PD-1 inhibitor with severe bloody diarrhea (8-10 stools/day), fever, and dehydration consistent with Grade 3 immune-related colitis. Failed low-dose steroids indicating need for escalation.\",\n    \"temporal_relationship\": \"During active immunotherapy\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"Bloody diarrhea\",\n      \"Failed low-dose steroids\",\n      \"Fever and dehydration\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 3 Diarrhea: \\u22657 stools/day over baseline OR bloody diarrhea. Patient has 8-10 stools with blood, meeting Grade 3 criteria.\",\n  \"urgency_reasoning\": \"Grade 3 colitis requires same-day evaluation and hospitalization for IV corticosteroids.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Hospitalize for IV methylprednisolone 1-2mg/kg\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 3 colitis requires IV steroids\"\n    },\n    {\n      \"action\": \"Discontinue nivolumab\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 3 toxicity requires treatment discontinuation\"\n    },\n    {\n      \"action\": \"GI consultation for colonoscopy\",\n      \"priority\": 1,\n      \"rationale\": \"Confirm diagnosis and assess severity\"\n    },\n    {\n      \"action\": \"IV fluid resuscitation\",\n      \"priority\": 1,\n      \"rationale\": \"Patient is dehydrated\"\n    }\n  ],\n  \"key_evidence\": [\n    \"8-10 bloody stools daily\",\n    \"Failed low-dose steroids\",\n    \"Fever\",\n    \"Dehydration\",\n    \"Elevated CRP\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: HEP-001\nAge: 52\nCancer Type: Urothelial carcinoma\n\nMEDICATIONS:\nAtezolizumab 1200mg IV q3weeks, Metformin 1000mg BID, Omeprazole 20mg daily\n\nLABORATORY VALUES:\nAST: 156 U/L (H) - baseline 28, ALT: 189 U/L (H) - baseline 32, ALP: 145 U/L (H), Total Bilirubin: 1.8 mg/dL (H), INR: 1.1\n\nSYMPTOMS:\nFatigue - moderate, Mild nausea, No jaundice, No abdominal pain\n\nCLINICAL NOTES:\nRoutine labs show AST/ALT elevation >3x ULN. Patient asymptomatic except for mild fatigue. No alcohol use. No new medications. Viral hepatitis panel pending.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 2 - Moderate\",\n  \"urgency\": \"soon\",\n  \"affected_systems\": [\n    \"Hepatic\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Possible\",\n    \"reasoning\": \"Patient on PD-L1 inhibitor with AST/ALT elevation 3-5x ULN consistent with Grade 2 immune-related hepatitis. Need to rule out viral hepatitis and drug-induced causes.\",\n    \"temporal_relationship\": \"During active immunotherapy\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"AST/ALT >3x ULN\",\n      \"No other hepatotoxic medications\"\n    ],\n    \"against_factors\": [\n      \"Viral hepatitis panel pending\",\n      \"Could be other etiology\"\n    ]\n  },\n  \"severity_reasoning\": \"CTCAE Grade 2 Hepatitis: AST/ALT >3-5x ULN. AST 156 (~4x ULN) and ALT 189 (~4.7x ULN) meet Grade 2 criteria.\",\n  \"urgency_reasoning\": \"Grade 2 hepatitis requires oncology review to determine need for treatment hold and corticosteroid initiation.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Hold atezolizumab pending evaluation\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 2 hepatitis requires treatment hold\"\n    },\n    {\n      \"action\": \"Rule out viral hepatitis (HAV, HBV, HCV)\",\n      \"priority\": 1,\n      \"rationale\": \"Must exclude infectious causes\"\n    },\n    {\n      \"action\": \"Consider prednisone 0.5-1mg/kg if viral negative\",\n      \"priority\": 2,\n      \"rationale\": \"Standard treatment for immune-related hepatitis\"\n    },\n    {\n      \"action\": \"Recheck LFTs in 3-5 days\",\n      \"priority\": 2,\n      \"rationale\": \"Monitor for progression\"\n    }\n  ],\n  \"key_evidence\": [\n    \"AST 156 U/L (>3x ULN)\",\n    \"ALT 189 U/L (>3x ULN)\",\n    \"On atezolizumab\",\n    \"Mildly elevated bilirubin\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: HEP-002\nAge: 48\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg + Nivolumab 1mg/kg IV q3weeks, Acetaminophen 500mg PRN\n\nLABORATORY VALUES:\nAST: 485 U/L (H), ALT: 612 U/L (H), ALP: 210 U/L (H), Total Bilirubin: 3.2 mg/dL (H), Direct Bilirubin: 2.1 mg/dL (H), INR: 1.4 (H), Albumin: 3.0 g/dL (L)\n\nSYMPTOMS:\nJaundice - visible scleral icterus, Fatigue - severe, Nausea and anorexia, Dark urine, Right upper quadrant discomfort\n\nCLINICAL NOTES:\nPatient on combination immunotherapy for metastatic melanoma. Developed jaundice over past week. AST/ALT >10x ULN. Hepatitis panel negative. No hepatotoxic medications. Ultrasound shows no biliary obstruction.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 3 - Severe\",\n  \"urgency\": \"urgent\",\n  \"affected_systems\": [\n    \"Hepatic\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on combination ICI (ipi/nivo) with severe transaminitis >10x ULN, jaundice, and elevated INR. Viral hepatitis ruled out. Classic presentation of Grade 3 immune-related hepatitis.\",\n    \"temporal_relationship\": \"During combination immunotherapy\",\n    \"supporting_factors\": [\n      \"Combination ICI (highest hepatitis risk)\",\n      \"AST/ALT >10x ULN\",\n      \"Jaundice with elevated bilirubin\",\n      \"Negative viral panel\",\n      \"No biliary obstruction\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 3 Hepatitis: AST/ALT >5-20x ULN. AST 485 (~12x ULN) and ALT 612 (~15x ULN) with elevated bilirubin and INR indicate severe hepatitis.\",\n  \"urgency_reasoning\": \"Grade 3 hepatitis requires same-day hospitalization for IV corticosteroids and close monitoring of synthetic function.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Permanently discontinue immunotherapy\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 3 hepatitis typically requires permanent discontinuation\"\n    },\n    {\n      \"action\": \"Hospitalize for IV methylprednisolone 1-2mg/kg\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 3 hepatitis requires IV steroids\"\n    },\n    {\n      \"action\": \"Hepatology consultation\",\n      \"priority\": 1,\n      \"rationale\": \"Severe hepatitis needs specialist input\"\n    },\n    {\n      \"action\": \"Monitor INR daily\",\n      \"priority\": 1,\n      \"rationale\": \"Elevated INR indicates synthetic dysfunction - monitor for acute liver failure\"\n    }\n  ],\n  \"key_evidence\": [\n    \"AST 485, ALT 612 (>10x ULN)\",\n    \"Jaundice\",\n    \"Elevated INR 1.4\",\n    \"Combination ICI\",\n    \"Negative viral panel\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: LUNG-001\nAge: 67\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nDurvalumab 10mg/kg IV q2weeks, Albuterol inhaler PRN, Lisinopril 20mg daily\n\nLABORATORY VALUES:\nWBC: 9.8 x10^9/L, LDH: 280 U/L (H), CRP: 3.2 mg/dL (H), Procalcitonin: 0.15 ng/mL\n\nSYMPTOMS:\nDry cough - new onset, 2 weeks, Dyspnea on exertion - moderate, No fever, O2 saturation: 94% on room air\n\nCLINICAL NOTES:\nPost-chemoradiation consolidation durvalumab. New dry cough and exertional dyspnea x 2 weeks. CT chest shows new bilateral ground-glass opacities. No infectious symptoms. Sputum culture negative.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 2 - Moderate\",\n  \"urgency\": \"soon\",\n  \"affected_systems\": [\n    \"Pulmonary\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on durvalumab post-chemoradiation (high pneumonitis risk setting) with new cough, dyspnea, and bilateral GGO on CT. Low procalcitonin and negative cultures argue against infection.\",\n    \"temporal_relationship\": \"During consolidation durvalumab after chemoradiation\",\n    \"supporting_factors\": [\n      \"Post-CRT durvalumab (10-15% pneumonitis rate)\",\n      \"New bilateral GGO on CT\",\n      \"Negative infection workup\",\n      \"Classic symptom pattern\"\n    ],\n    \"against_factors\": [\n      \"O2 sat 94% - borderline\"\n    ]\n  },\n  \"severity_reasoning\": \"CTCAE Grade 2 Pneumonitis: Symptomatic, medical intervention indicated, limiting instrumental ADL. Patient has moderate dyspnea on exertion with O2 sat 94%.\",\n  \"urgency_reasoning\": \"Grade 2 pneumonitis requires oncology review to initiate corticosteroids and determine need for treatment hold.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Hold durvalumab\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 2 pneumonitis requires treatment hold\"\n    },\n    {\n      \"action\": \"Start prednisone 1-2mg/kg daily\",\n      \"priority\": 1,\n      \"rationale\": \"Standard treatment for Grade 2 pneumonitis\"\n    },\n    {\n      \"action\": \"Bronchoscopy with BAL if diagnostic uncertainty\",\n      \"priority\": 2,\n      \"rationale\": \"Can confirm diagnosis and rule out infection\"\n    },\n    {\n      \"action\": \"Follow-up CT in 3-4 weeks\",\n      \"priority\": 2,\n      \"rationale\": \"Assess response to steroids\"\n    }\n  ],\n  \"key_evidence\": [\n    \"New bilateral GGO on CT\",\n    \"Dry cough and dyspnea\",\n    \"O2 sat 94%\",\n    \"Low procalcitonin\",\n    \"Negative cultures\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: LUNG-002\nAge: 71\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Oxygen 4L NC, Azithromycin 500mg daily (started empirically)\n\nLABORATORY VALUES:\nWBC: 11.5 x10^9/L, LDH: 450 U/L (H), CRP: 12.5 mg/dL (H), PaO2: 58 mmHg on 4L NC, Procalcitonin: 0.2 ng/mL\n\nSYMPTOMS:\nSevere dyspnea at rest, Persistent dry cough, Hypoxia requiring supplemental O2, Tachypnea - RR 28, No fever\n\nCLINICAL NOTES:\nPatient on pembrolizumab for stage IV NSCLC. Progressive dyspnea over 1 week, now requiring 4L O2. CT shows extensive bilateral GGO and consolidation. BAL cultures negative. Considering ICU transfer.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 3 - Severe\",\n  \"urgency\": \"emergency\",\n  \"affected_systems\": [\n    \"Pulmonary\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on pembrolizumab with severe hypoxemia (PaO2 58) requiring supplemental O2, extensive bilateral GGO/consolidation on CT, and negative infection workup. Classic severe immune-related pneumonitis.\",\n    \"temporal_relationship\": \"During active immunotherapy\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"Severe hypoxemia requiring O2\",\n      \"Extensive bilateral infiltrates\",\n      \"Negative BAL cultures\",\n      \"Low procalcitonin\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 3 Pneumonitis: Severe symptoms, oxygen indicated, limiting self-care ADL. PaO2 58 on 4L O2 with tachypnea indicates severe respiratory compromise.\",\n  \"urgency_reasoning\": \"Grade 3 pneumonitis with significant hypoxemia requires emergency evaluation and ICU admission for high-dose IV steroids.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Permanently discontinue pembrolizumab\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 3 pneumonitis requires permanent discontinuation\"\n    },\n    {\n      \"action\": \"IV methylprednisolone 2-4mg/kg/day\",\n      \"priority\": 1,\n      \"rationale\": \"High-dose IV steroids for severe pneumonitis\"\n    },\n    {\n      \"action\": \"ICU admission for monitoring\",\n      \"priority\": 1,\n      \"rationale\": \"Severe hypoxemia requires close monitoring\"\n    },\n    {\n      \"action\": \"Pulmonology consultation\",\n      \"priority\": 1,\n      \"rationale\": \"Specialist input for severe pneumonitis\"\n    },\n    {\n      \"action\": \"Consider infliximab if no response in 48h\",\n      \"priority\": 2,\n      \"rationale\": \"Steroid-refractory pneumonitis may need additional immunosuppression\"\n    }\n  ],\n  \"key_evidence\": [\n    \"PaO2 58 on 4L O2\",\n    \"Extensive bilateral GGO\",\n    \"Tachypnea RR 28\",\n    \"Negative BAL cultures\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: ENDO-001\nAge: 55\nCancer Type: Renal cell carcinoma\n\nMEDICATIONS:\nNivolumab 240mg IV q2weeks, Amlodipine 5mg daily\n\nLABORATORY VALUES:\nTSH: 28.5 mIU/L (H) - baseline 2.1, Free T4: 0.4 ng/dL (L), Free T3: 1.8 pg/mL (L), Anti-TPO: positive\n\nSYMPTOMS:\nFatigue - progressive over 4 weeks, Weight gain - 8 lbs in 1 month, Cold intolerance, Constipation, Dry skin\n\nCLINICAL NOTES:\nPatient on nivolumab for metastatic RCC. Progressive fatigue and weight gain over past month. TSH markedly elevated with low free T4. Classic hypothyroid symptoms present.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 2 - Moderate\",\n  \"urgency\": \"soon\",\n  \"affected_systems\": [\n    \"Endocrine\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on PD-1 inhibitor with markedly elevated TSH, low free T4, positive anti-TPO antibodies, and classic hypothyroid symptoms. This is immune-related thyroiditis causing hypothyroidism.\",\n    \"temporal_relationship\": \"During active immunotherapy\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"TSH 28.5 (very elevated)\",\n      \"Low free T4\",\n      \"Anti-TPO positive\",\n      \"Classic symptoms\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 2 Hypothyroidism: Symptomatic, thyroid replacement indicated. Patient has overt hypothyroidism with classic symptoms.\",\n  \"urgency_reasoning\": \"Hypothyroidism requires oncology review but is not urgent. Importantly, immunotherapy can typically be CONTINUED with thyroid hormone replacement.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Start levothyroxine replacement\",\n      \"priority\": 1,\n      \"rationale\": \"Overt hypothyroidism requires hormone replacement\"\n    },\n    {\n      \"action\": \"Can continue nivolumab\",\n      \"priority\": 2,\n      \"rationale\": \"Unlike other irAEs, hypothyroidism does not require ICI discontinuation\"\n    },\n    {\n      \"action\": \"Recheck TSH in 6-8 weeks\",\n      \"priority\": 2,\n      \"rationale\": \"Monitor response to replacement therapy\"\n    },\n    {\n      \"action\": \"Endocrinology referral if needed\",\n      \"priority\": 3,\n      \"rationale\": \"For dose adjustment and long-term management\"\n    }\n  ],\n  \"key_evidence\": [\n    \"TSH 28.5 mIU/L\",\n    \"Free T4 0.4 ng/dL\",\n    \"Anti-TPO positive\",\n    \"Classic hypothyroid symptoms\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: ENDO-002\nAge: 62\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg IV q3weeks (4th dose), Hydrochlorothiazide 25mg daily\n\nLABORATORY VALUES:\nACTH: 5 pg/mL (L), Cortisol (AM): 2.1 ug/dL (L), TSH: 0.5 mIU/L (L), Free T4: 0.6 ng/dL (L), LH: 1.2 mIU/mL (L), FSH: 2.0 mIU/mL (L), Testosterone: 85 ng/dL (L), Prolactin: 45 ng/mL (H)\n\nSYMPTOMS:\nSevere headache - frontal, Profound fatigue, Nausea, Visual disturbance - none, Dizziness on standing\n\nCLINICAL NOTES:\nPatient after 4th dose of ipilimumab for melanoma. New severe headache and fatigue over past week. Labs show panhypopituitarism pattern. MRI pituitary shows enlarged gland with heterogeneous enhancement.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 3 - Severe\",\n  \"urgency\": \"urgent\",\n  \"affected_systems\": [\n    \"Endocrine\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on ipilimumab (CTLA-4 inhibitor with 5-10% hypophysitis rate) with panhypopituitarism pattern (low ACTH, cortisol, TSH, gonadotropins) and MRI showing enlarged pituitary. Classic immune-related hypophysitis.\",\n    \"temporal_relationship\": \"After 4th dose of ipilimumab\",\n    \"supporting_factors\": [\n      \"Ipilimumab (highest hypophysitis risk)\",\n      \"Panhypopituitarism labs\",\n      \"MRI showing enlarged pituitary\",\n      \"Classic headache presentation\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 3: Severe symptoms with adrenal insufficiency (cortisol 2.1). Low cortisol is life-threatening and requires immediate treatment.\",\n  \"urgency_reasoning\": \"Adrenal insufficiency is life-threatening. Patient needs immediate stress-dose hydrocortisone to prevent adrenal crisis.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"IMMEDIATE stress-dose hydrocortisone 100mg IV\",\n      \"priority\": 1,\n      \"rationale\": \"Adrenal insufficiency is life-threatening - cortisol replacement is critical\"\n    },\n    {\n      \"action\": \"Hold ipilimumab\",\n      \"priority\": 1,\n      \"rationale\": \"Grade 3 hypophysitis requires treatment hold\"\n    },\n    {\n      \"action\": \"Endocrinology consultation urgent\",\n      \"priority\": 1,\n      \"rationale\": \"Specialist input for hormone replacement\"\n    },\n    {\n      \"action\": \"Start thyroid replacement AFTER cortisol\",\n      \"priority\": 2,\n      \"rationale\": \"CRITICAL: Starting levothyroxine before cortisol can precipitate adrenal crisis\"\n    }\n  ],\n  \"key_evidence\": [\n    \"Cortisol 2.1 ug/dL (critically low)\",\n    \"ACTH 5 pg/mL (low)\",\n    \"Panhypopituitarism pattern\",\n    \"MRI shows enlarged pituitary\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: CARD-001\nAge: 61\nCancer Type: Melanoma\n\nMEDICATIONS:\nIpilimumab 3mg/kg + Nivolumab 1mg/kg IV q3weeks, Metoprolol 25mg BID, Lisinopril 10mg daily\n\nLABORATORY VALUES:\nTroponin I: 2.8 ng/mL (H), CK-MB: 45 ng/mL (H), BNP: 850 pg/mL (H), CRP: 8.5 mg/dL (H), CK: 1200 U/L (H)\n\nSYMPTOMS:\nChest pain - substernal, worse with exertion, Dyspnea - progressive, Palpitations, Fatigue - severe, Orthopnea\n\nCLINICAL NOTES:\nPatient on combination ipilimumab/nivolumab for melanoma. Chest pain and dyspnea started 5 days ago. ECG shows diffuse ST changes and low voltage. Echo shows EF 35% (baseline 60%). Troponin elevated. Urgent cardiology consult for suspected ICI myocarditis.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 4 - Life-threatening\",\n  \"urgency\": \"emergency\",\n  \"affected_systems\": [\n    \"Cardiac\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on combination ICI with elevated troponin, significantly reduced EF (60% to 35%), elevated BNP, ECG changes, and classic symptoms. This is immune-related myocarditis which has 25-50% mortality.\",\n    \"temporal_relationship\": \"During combination immunotherapy\",\n    \"supporting_factors\": [\n      \"Combination ICI (highest myocarditis risk)\",\n      \"Troponin 2.8 ng/mL\",\n      \"EF drop from 60% to 35%\",\n      \"ECG changes\",\n      \"Elevated CK (possible concurrent myositis)\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 4: Life-threatening cardiac dysfunction. Troponin elevation with significant EF reduction indicates severe myocardial injury with high mortality risk.\",\n  \"urgency_reasoning\": \"ICI myocarditis has 25-50% mortality rate. This is a MEDICAL EMERGENCY requiring immediate ICU admission and high-dose steroids.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"IMMEDIATE permanent discontinuation of all ICIs\",\n      \"priority\": 1,\n      \"rationale\": \"Myocarditis requires permanent discontinuation\"\n    },\n    {\n      \"action\": \"ICU admission with continuous telemetry\",\n      \"priority\": 1,\n      \"rationale\": \"High risk of arrhythmia and hemodynamic collapse\"\n    },\n    {\n      \"action\": \"IV methylprednisolone 1g daily\",\n      \"priority\": 1,\n      \"rationale\": \"High-dose steroids for life-threatening myocarditis\"\n    },\n    {\n      \"action\": \"Emergent cardiology consultation\",\n      \"priority\": 1,\n      \"rationale\": \"Specialist input critical for management\"\n    },\n    {\n      \"action\": \"Serial troponin and telemetry monitoring\",\n      \"priority\": 1,\n      \"rationale\": \"Monitor for progression\"\n    },\n    {\n      \"action\": \"Have IVIG and plasmapheresis available\",\n      \"priority\": 2,\n      \"rationale\": \"May need escalation if steroid-refractory\"\n    }\n  ],\n  \"key_evidence\": [\n    \"Troponin I 2.8 ng/mL\",\n    \"EF 35% (baseline 60%)\",\n    \"BNP 850\",\n    \"ECG changes\",\n    \"Combination ICI\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: NEURO-001\nAge: 68\nCancer Type: Small cell lung cancer\n\nMEDICATIONS:\nNivolumab 240mg IV q2weeks, Pyridostigmine 60mg TID (started 2 days ago)\n\nLABORATORY VALUES:\nCK: 180 U/L, Acetylcholine receptor antibodies: positive, Anti-striated muscle antibodies: positive, Troponin: 0.08 ng/mL (slightly elevated)\n\nSYMPTOMS:\nBilateral ptosis, Diplopia, Dysphagia - mild, Proximal muscle weakness, Fatigue worse with activity\n\nCLINICAL NOTES:\nPatient on nivolumab for extensive stage SCLC. Developed ptosis and diplopia over 1 week. Fatigable weakness on exam. Ice pack test positive. AChR antibodies positive. Concerned for irAE MG. Monitor for respiratory involvement.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 2 - Moderate\",\n  \"urgency\": \"urgent\",\n  \"affected_systems\": [\n    \"Neurologic\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on PD-1 inhibitor with positive AChR antibodies, positive anti-striated muscle antibodies, and classic MG symptoms (ptosis, diplopia, fatigable weakness). The anti-striated muscle antibodies indicate 20-40% risk of concurrent myocarditis.\",\n    \"temporal_relationship\": \"During active immunotherapy\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"AChR antibodies positive\",\n      \"Anti-striated muscle antibodies positive\",\n      \"Classic MG symptoms\",\n      \"Slightly elevated troponin\"\n    ],\n    \"against_factors\": []\n  },\n  \"severity_reasoning\": \"CTCAE Grade 2 but URGENT due to MG crisis risk and concurrent myocarditis concern. Dysphagia indicates bulbar involvement.\",\n  \"urgency_reasoning\": \"ICI-related MG can progress rapidly to respiratory failure. Anti-striated muscle antibodies + elevated troponin suggest possible concurrent myocarditis. Requires urgent evaluation.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Permanently discontinue nivolumab\",\n      \"priority\": 1,\n      \"rationale\": \"ICI-related MG requires permanent discontinuation\"\n    },\n    {\n      \"action\": \"Neurology consultation urgent\",\n      \"priority\": 1,\n      \"rationale\": \"Specialist input for MG management\"\n    },\n    {\n      \"action\": \"Serial FVC monitoring q4-6h\",\n      \"priority\": 1,\n      \"rationale\": \"Monitor for MG crisis and respiratory failure\"\n    },\n    {\n      \"action\": \"Check troponin daily and get cardiac workup\",\n      \"priority\": 1,\n      \"rationale\": \"Anti-striated muscle antibodies indicate myocarditis risk\"\n    },\n    {\n      \"action\": \"Start prednisone 1mg/kg\",\n      \"priority\": 1,\n      \"rationale\": \"Steroids for immune-related MG\"\n    }\n  ],\n  \"key_evidence\": [\n    \"AChR antibodies positive\",\n    \"Anti-striated muscle antibodies positive\",\n    \"Troponin 0.08\",\n    \"Ptosis and diplopia\",\n    \"Dysphagia\"\n  ]\n}"}]}
{"messages": [{"role": "user", "content": "You are a clinical oncology AI assistant specializing in detecting immune-related adverse events (irAEs) in patients on checkpoint inhibitor immunotherapy.\n\nAnalyze the following patient data and provide a structured assessment:\n\nPatient ID: NEURO-002\nAge: 54\nCancer Type: Non-small cell lung cancer\n\nMEDICATIONS:\nPembrolizumab 200mg IV q3weeks, Levetiracetam 1000mg BID (started after seizure), Methylprednisolone 1g IV daily\n\nLABORATORY VALUES:\nCSF: WBC 45 (lymphocyte predominant), CSF protein: 85 mg/dL (H), CSF glucose: 55 mg/dL (normal), MRI brain: bilateral medial temporal lobe hyperintensity\n\nSYMPTOMS:\nConfusion - acute onset, Memory impairment, Seizure - witnessed generalized tonic-clonic, Headache, Personality change\n\nCLINICAL NOTES:\nPatient on pembrolizumab for NSCLC. Acute confusion and witnessed seizure 3 days ago. MRI shows bilateral medial temporal lobe T2 hyperintensity. LP shows lymphocytic pleocytosis. Autoimmune encephalitis workup sent. Started high-dose steroids.\n\nBased on CTCAE v5.0 grading criteria and ASCO irAE management guidelines, provide your assessment in JSON format with the following structure:\n- irae_detected (boolean)\n- overall_severity (Grade 1-4 or Unknown)\n- urgency (routine/soon/urgent/emergency)\n- affected_systems (list of organ systems)\n- causality (likelihood, reasoning, temporal_relationship, supporting_factors, against_factors)\n- severity_reasoning (explanation of CTCAE grade)\n- urgency_reasoning (explanation of triage level)\n- recommended_actions (list with action, priority, rationale)\n- key_evidence (list of key findings)\n\nIMPORTANT RULES:\n1. Grade 2 irAEs require at minimum \"soon\" urgency (oncology review needed)\n2. Grade 3 irAEs require at minimum \"urgent\" urgency\n3. Grade 4 irAEs or cardiac/neuro involvement require \"emergency\" urgency\n4. Always err on the side of higher urgency for patient safety"}, {"role": "assistant", "content": "{\n  \"irae_detected\": true,\n  \"overall_severity\": \"Grade 3 - Severe\",\n  \"urgency\": \"emergency\",\n  \"affected_systems\": [\n    \"Neurologic\"\n  ],\n  \"causality\": {\n    \"likelihood\": \"Highly likely\",\n    \"reasoning\": \"Patient on pembrolizumab with acute encephalopathy, seizure, bilateral medial temporal lobe MRI findings (limbic encephalitis pattern), and inflammatory CSF (lymphocytic pleocytosis with elevated protein). Classic immune-related encephalitis.\",\n    \"temporal_relationship\": \"During active immunotherapy\",\n    \"supporting_factors\": [\n      \"On checkpoint inhibitor\",\n      \"Limbic encephalitis pattern on MRI\",\n      \"Inflammatory CSF\",\n      \"Seizure\",\n      \"Acute confusion\"\n    ],\n    \"against_factors\": [\n      \"Normal CSF glucose argues against infectious meningitis\"\n    ]\n  },\n  \"severity_reasoning\": \"CTCAE Grade 3-4: Seizure and significant encephalopathy indicate severe neurologic toxicity requiring ICU-level monitoring.\",\n  \"urgency_reasoning\": \"Immune-related encephalitis with seizure is a neurologic emergency requiring ICU admission, high-dose steroids, and close monitoring.\",\n  \"recommended_actions\": [\n    {\n      \"action\": \"Permanently discontinue pembrolizumab\",\n      \"priority\": 1,\n      \"rationale\": \"Severe neurologic toxicity requires permanent discontinuation\"\n    },\n    {\n      \"action\": \"Continue IV methylprednisolone 1g daily x 3-5 days\",\n      \"priority\": 1,\n      \"rationale\": \"High-dose steroids for encephalitis\"\n    },\n    {\n      \"action\": \"Neurology consultation urgent\",\n      \"priority\": 1,\n      \"rationale\": \"Specialist input critical\"\n    },\n    {\n      \"action\": \"EEG monitoring\",\n      \"priority\": 1,\n      \"rationale\": \"Monitor for subclinical seizures\"\n    },\n    {\n      \"action\": \"ICU admission for neuro monitoring\",\n      \"priority\": 1,\n      \"rationale\": \"Encephalitis with seizure requires close monitoring\"\n    },\n    {\n      \"action\": \"Consider IVIG if steroid-refractory\",\n      \"priority\": 2,\n      \"rationale\": \"May need additional immunosuppression\"\n    }\n  ],\n  \"key_evidence\": [\n    \"Bilateral medial temporal hyperintensity\",\n    \"CSF WBC 45 (lymphocytic)\",\n    \"CSF protein 85\",\n    \"Witnessed seizure\",\n    \"Acute confusion\"\n  ]\n}"}]}
